ERBB2 and breast carcinoma: While there is limited information on the number of breast cancer patients receiving neoadjuvant HER2 targeted therapy, the percentage of HER2-positive breast cancer patients receiving adjuvant trastuzumab was around 60% in Sri Lanka30.